Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

877

Full text

607

Free full text

329

Publication Types

Journal Article

891

Randomized Controlled Trial

435

Research Support, Non-U.S. Gov't

401

Review

290

Multicenter Study

193

Comparative Study

181

Clinical Trial

110

Research Support, N.I.H., Extramural

Meta-Analysis

Observational Study

Systematic Review

Clinical Trial, Phase III

Controlled Clinical Trial

Clinical Trial, Phase IV

Comment

Research Support, U.S. Gov't, P.H.S.

Retracted Publication

Editorial

Clinical Trial, Phase II

Letter

Research Support, U.S. Gov't, Non-P.H.S.

Case Reports

Clinical Trial, Phase I

Pragmatic Clinical Trial

Network Meta-Analysis

Clinical Trial Protocol

Clinical Conference

Publication Year

From

Quick links

Individual year

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for

""Angiotensin II Type 1 Receptor Blockers""[mesh_terms]

900 Results

Searching titles within these results

Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals.

Tonous N Silfani, J Findlay Walker, Suzanne Oparil

American journal of hypertension 2005;18(2 Pt 1):287-94

Full Text

Abstract

Angiotensin blockade to reduce microvascular damage in diabetes mellitus.

Stephan Martin, Gabriele E Lang, Roland E Schmieder, Michael Böhm, Peter Bramlage

Deutsches Arzteblatt international 2009;106(34-35):556-62

Free Full Text

Abstract

Roles of bone morphogenetic protein-6 in aldosterone regulation by adrenocortical cells.

Hiroyuki Otani, Fumio Otsuka, Kenichi Inagaki, Jiro Suzuki, Hirofumi Makino

Acta medica Okayama 2010;64(4):213-8

Free Full Text

Abstract

Cutaneous effects of antihypertensive drugs.

Danilo Baccino, Giulia Merlo, Emanuele Cozzani, Gian M Rosa, Giacomo Tini, Martina Burlando, Aurora Parodi

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 2021;155(2):202-211

Full Text

Abstract

Current concepts in diastolic heart failure.

Sunil Dhar, Deepak Koul, Gilbert E D'Alonzo

The Journal of the American Osteopathic Association 2008;108(4):203-9

Full Text

Abstract

Educational paper. Connective tissue disorders with vascular involvement: from gene to therapy.

Dorien Proost, Lut Van Laer, Bart L Loeys

European journal of pediatrics 2014;172(8):997-1005

Free Full Text

Abstract

Valsartan use in pediatric hypertension.

Kevin E C Meyers, Brittany Behar

Future cardiology 2011;7(2):151-9

Full Text

Abstract

Beating the clock: reducing cardiovascular risk by rapid blood pressure reduction with olmesartan.

Carlos Escobar, Vivencio Barrios

Expert opinion on pharmacotherapy 2010;11(9):1549-58

Full Text

Abstract

Combination therapy in the management of hypertension: focus on angiotensin receptor blockers combined with diuretics.

Paolo Palatini

Journal of clinical hypertension (Greenwich, Conn.) 2005;7(2):96-101

Free Full Text

Abstract

Management of cardiovascular risk with RAS inhibitor/CCB combination therapy.

B Dahlöf

Journal of human hypertension 2009;23(2):77-85

Full Text

Abstract

Angiotensin II antagonists--therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy.

Artur Beltrame Ribeiro

Current medical research and opinion 2006;22(1):1-16

Full Text

Abstract

Prehypertension: should we be treating with pharmacologic therapy?

Brent M Egan, Shawna D Nesbitt, Stevo Julius

Therapeutic advances in cardiovascular disease 2009;2(4):305-14

Free Full Text

Abstract

Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy.

Michael Weber, Suzanne Oparil

Postgraduate medicine 2009;121(2):25-39

Full Text

Abstract

Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?

Heinz Rupp

Current medical research and opinion 2008;23 Suppl 5():S25-9

Full Text

Abstract

The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy.

J N Basile, S Chrysant

Journal of human hypertension 2006;20(3):169-75

Full Text

Abstract

Results: 1 – 15 / 900

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Angiotensin II Type 1 Receptor Blockers""[mesh_terms]

Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals.

Angiotensin blockade to reduce microvascular damage in diabetes mellitus.

Roles of bone morphogenetic protein-6 in aldosterone regulation by adrenocortical cells.

Cutaneous effects of antihypertensive drugs.

Current concepts in diastolic heart failure.

Educational paper. Connective tissue disorders with vascular involvement: from gene to therapy.

Valsartan use in pediatric hypertension.

Beating the clock: reducing cardiovascular risk by rapid blood pressure reduction with olmesartan.

Combination therapy in the management of hypertension: focus on angiotensin receptor blockers combined with diuretics.

Management of cardiovascular risk with RAS inhibitor/CCB combination therapy.

Angiotensin II antagonists--therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy.

Prehypertension: should we be treating with pharmacologic therapy?

Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy.

Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?

The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy.

Results for

""Angiotensin II Type 1 Receptor Blockers""[mesh_terms]